Hypoxic regions within solid tumors are often resistant to chemotherapy and radiation. BNIP3 (Bcl-2/E1B 19 kDa interacting protein) is a proapoptotic member of the Bcl-2 family that is expressed in hypoxic regions of tumors. During hypoxia, BNIP3 expression is increased in many cell types and upon forced overexpression BNIP3 induces cell death. Herein, we have demonstrated that blockage of hypoxia-induced BNIP3 expression using antisense oligonucleotides against BNIP3 or blockage of BNIP3 function through expression of a mutant form of BNIP3 inhibits hypoxia-induced cell death in human embryonic kidney 293 cells. We have also determined that hypoxiamediated BNIP3 expression is regulated by the transcription factor, hypoxia-inducible factor-1a (HIF-1a) in human epithelial cell lines. Furthermore, HIF-1a directly binds to a consensus HIF-1a-responsive element (HRE) in the human BNIP3 promoter that upon mutation of this HRE site eliminates the hypoxic responsiveness of the promoter. Since BNIP3 is expressed in hypoxic regions of tumors but fails to induce cell death, we determined whether growth factors block BNIP3-induced cell death. Treatment of the breast cancer cell line MCF-7 cells with epidermal growth factor (EGF) or insulin-like growth factor effectively protected these cells from BNIP3-induced cell death. Furthermore, inhibiting EGF receptor signaling using antibodies against ErbB2 (Herceptin) resulted in increased hypoxia-induced cell death in MCF-7 cells. Taken together, BNIP3 plays a role in hypoxia-induced cell death in human epithelial cells that could be circumvented by growth factor signaling.
Introduction
Hypoxic microenvironments often emerge in solid tumors derived from epithelial cells. These hypoxic regions often correlate with poor prognosis due to the ability of cells within these regions to become resistant to chemotherapeutic agents and radiation therapy (Caro, 2001; Knowles and Harris, 2001; Harris, 2002; Hochachka et al., 2002) . By understanding the regulation of hypoxia-induced cell death, effective treatments against cancerous tumors can be developed.
Bcl-2/E1B 19 kDa interacting protein (BNIP3) is a unique member of the Bcl2 family members that is upregulated under hypoxic conditions (Chen et al., 1997; Cizeau et al., 2000) . Forced overexpression of BNIP3 induces cell death characterized by localization at the mitochondria, opening of the permeability transition (PT) pore, loss of membrane potential (Dc m ) and reactive oxygen species (ROS) production . Electron microscopy (EM) images show extensive cytoplasmic vacuolization and the formation of electron-dense bodies following BNIP3 expression. In addition, BNIP3-induced cell death is independent of cytochrome c release from the mitochondria and caspase activation in fibroblast and epithelial cells . BNIP3 is also implicated in ischemiainduced apoptosis in rat cardiomyocytes (Kubasiak et al., 2002; Regula et al., 2002) . It remains to be determined, however, whether hypoxia-mediated BNIP3 expression in human epithelial cells is involved in hypoxia-induced cell death.
BNIP3 structure is similar to other Bcl2 family members since it contains a C-terminal transmembrane (TM) domain that targets the protein to the mitochondria and is required to induce cell death . The BNIP3 protein also contains a Bcl-2 homology 3 (BH3) domain as determined by sequence consensus with other BH3 domains in the Bcl-2 family, but in contrast to other Bcl-2 family members, deletion of the domain does not affect its killing activity . BNIP3-induced cell death is blocked by overexpression of Bcl2, but unlike other pro-cell death Bcl2 family members, Bcl2 fails to associate with the BH3 domain of BNIP3 instead Bcl2 associates with the TM domain of BNIP3 . Thus, the function of the BH3 domain in BNIP3 is still unclear.
Besides BNIP3, the transcription factor, hypoxiainducible factor-1a (HIF-1a) is increased and activated during hypoxia (Piret et al., 2002; Semenza, 2002a) . Under oxygenated (normoxic) condition, HIF-1a is targeted for degradation, but in the absence of oxygen, this degradation is blocked resulting in the translocation of the transcription factor to the nucleus and the activation of target genes (Giatromanolaki and Hon et al., 2002; Piret et al., 2002; Sang et al., 2002; Semenza, 2002b) . Overexpression of von HippelLindau protein that suppresses HIF-1 levels inhibits hypoxia-induced BNIP3 expression (Sowter et al., 2001) . In rodent fibroblasts, HIF-1a activation was demonstrated to activate the rodent BNIP3 promoter (Bruick, 2000) . This activation is regulated by a putative HIF-1a-responsive element (HRE) in this promoter. The ability of HIF-1a to directly bind to this HRE site or the hypoxia regulation of the human BNIP3 promoter remains to be determined.
Many tumors express growth factors and their corresponding receptors that contribute to cancer progression (Kumar, 1998; Hung and Lau, 1999; Furstenberger and Senn, 2002) . Two such growth factors that contribute to tumor progression are epidermal growth factor (EGF) and insulin-like growth factor (IGF) (Hung and Lau, 1999; Furstenberger and Senn, 2002) . Treatment with these growth factors protects cells from various apoptotic stimuli (Kulik et al., 1997; Gibson et al., 1999; Gibson et al., 2002) . BNIP3 is expressed in hypoxic regions of epithelialderived tumors, but fails to induce cell death in these hypoxic cells (Sowter et al., 2001) . The ability of many growth factors to protect epithelial-derived cells against BNIP3 and hypoxia-mediated cell death is, however, unknown.
In this study, we have determined that BNIP3 expression plays a role in hypoxia-induced cell death in human epithelial-derived cells. In addition, hypoxiainduced BNIP3 expression is mediated by HIF-1a binding to a HRE site in the human BNIP3 promoter. Finally, we have determined that BNIP3-and hypoxiainduced cell death is blocked by growth factor signaling in human epithelial-derived cells. This suggests that BNIP3 plays a role in hypoxia-induced cell death, but is blocked by growth factor signaling in cancer cells.
Materials and methods

Cell culture
Human embryonic kidney (HEK) 293 and 293T (middle T antigen transformed) cells were cultured in Dulbecco's modified essential medium (DMEM) (GIBCO, BRL) supplemented with 10% fetal bovine serum (FBS) (GIBCO, BRL) and 100 U/ml penicillin/streptomycin (GIBCO, BRL) unless otherwise stated. Breast carcinoma MCF-7 cells were maintained in a-minimal essential medium (a-MEM) (GIBCO, BRL) supplemented with 10% FBS, 1% MEM sodium pyruvate (GIBCO, BRL), 1% HEPES (GIBCO, BRL) and 1% l-glutamine (GIBCO, BRL) and antibiotics unless otherwise stated. Chinese Hamster Ovary (CHO) parental cell line and CHO HIF-1a-defective cell line (CHO KA13) (gift from A Harris, Institute of Molecular Medicine, UK) were cultured in F:12 medium supplemented with 10% FBS, 1% lglutamine (GIBCO, BRL) and antibiotics. All cell lines were grown in a humidified incubator in the presence of 5% CO 2 at 371C. Cells were maintained under hypoxic conditions at 371C within a hypoxic chamber (Forma Scientific, Marietta, OH, USA) filled with 5% CO 2 balanced with N 2 .
Western blot analysis
MCF-7 and HEK293T cells were homogenized in a lysis buffer containing 50 mm Tris HCl (pH 7.4), 250 mm NaCl, 0.5% NP40, 50 mm NaF, 15 mm sodium pyrophosphate, 1 mm glycerophosphate, 1 mm Na 3 VO 4 , 500 nM okadeic acid, 20 mg aprotinin/ml, 0.7 mg pepstatin/ml, 5 mg leupeptin/ml, and 1 mm PMSF. Protein extracts were resolved on a 10% SDSpolyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred electrophoretically onto a nitrocellulose membrane (Bio-Rad laboratories Canada Ltd., Mississauga, ON, Canada). BNIP3 protein and HIF-1a protein were detected using a mouse anti-human BNIP3 monoclonal antibody and a mouse anti-human HIF-1a monoclonal antibody (BD Transduction Laboratories, Mississauga, ON, Canada) respectively. Goat anti-mouse horseradish peroxidase (BioRad laboratories Canada Ltd., Mississauga, ON, Canada) and enhanced chemiluminescence developing reagents (PerkinElmer Life Science) were used to detect the immunoreactive bands.
b-galactosidase viability assay HEK293T (1 Â 10 5 cells) were seeded in six-well plates. The next day, using lipofectamine reagent (Invitrogen) cells were transfected with 0.2 mg of pcDNA3-b-galactosidase (pcDNA3-b-gal) plasmid plus 1 mg of pcDNA3-BNIP3DTM. After 4 h transfection, cells were incubated either in DMEM under normoxic or hypoxic conditions for 48 h. Following incubation, cells were fixed in 0.2% glutaraldehyde and washed three times with 0.1 m phosphate buffer saline (PBS) and stained in X-gal buffer (0.5 mg/ml 5-bromo-4-chloro-3-indolyl-b-d-galactopyranoside, 3 mm K 3 Fe(CN) 6 , 3 mm K 4 Fe(CN) 6 3H 2 O, 1 mm MgCl 2 in 0.1 m PBS) to detect for b-galactosidase expression as described previously (Miura and Yuan J, 2000) . The percentage of dead cells was calculated by assessing the number of round, condensed, blue cells in the total population of flat blue cells. A total number of at least 200 cells were counted for each experiment. To assess for the effect of EGF on BNIP3 overexpressing cells, MCF-7 (8 Â 10 4 cells) were seeded in six-well plates for 24 h. The next day cells were incubated with EGF (1 mg/ml) (Sigma Aldrich, Oakville, ON, Canada) for 1 h. Using lipofectamine reagent, cells were transfected with 0.2 mg of pcDNA3-b-galactosidase and 1 mg of pcDNA3-BNIP3-3 0 T7 in the presence of EGF (1 mg/ml). After 4 h transfection, DMEM containing serum and EGF (1 mg/ml) were added to the cells and incubated at 371C. Following incubation, cells were stained as described previously to assess for b-galactosidase expression. The percentage of dead cells was calculated by assessing the number of round, condensed, blue cells in the total population of flat blue cells. A total number of at least 200 cells were counted for each experiment.
BNIP3 regulates hypoxia-induced cell death S Kothari et al Acridine orange cell death assay MCF-7 cells were treated with antibody against ErbB1 (Herceptin) (Roche, Mississauga, ON, Canada) ranging from 0.1 to 100 mg/ml for 0-96 h. Cells were then resuspended in 100 ml of media by gently vortexing, and 4 ml of acridine orange (100 mg/ml) and ethidium bromide (100 mg/ml) were added. A 10 ml aliquot was removed and placed on a microscope slide, and a coverslip was applied over the cells. The slide was viewed on a fluorescence microscope using a fluorescein filter. The percentage of dead cells was calculated by counting the number of orange cells and cells containing bright green local DNA condensation in a population of diffused green cells. A total number of at least 250 cells were counted for each assay.
BNIP3 promoter isolation
Recombinant luciferase plasmids were constructed as described in Chen et al. (1997) . Briefly, BAC clone H_NH0045A17 containing the human BNIP3 genomic sequence was used as template with appropriate primers to amplify 1193 bp of the BNIP3 promoter (À12 to À1205 bp). Primers were designed to incorporate appropriate restriction enzyme sites at the 5 0 and the 3 0 ends by polymerase chain reaction (PCR). Following restriction digestion, the inserts were ligated upstream of the luciferase gene into the pGL3-basic (Promega, Madison, WI, USA) reporter vector. BNIP3 promoter HRE mutants were generated by PCR, using sitedirected mutagenesis that mutated each of the two potential HRE. The BNIP3 promoters containing mutated HRE were ligated into the pGL3-basic reporter vector.
Transfection and reporter assays
HEK293, MCF-7 and CHO parental and CHO KA13 cells were plated onto 6 mm plates (1 Â 10 5 cells) in 5 ml of DMEM, a-MEM or F12 media supplemented with 10% FBS for 48 h before transfection. Cells were transfected using the lipofectamine reagent. For each transfection, 0.9 mg of the pGL3-BNIP3 plasmid and 0.1 mg of pCDNA3-b-gal reporter vector or 0.5 mg of pGL3-BNIP3 and 2.5 mg of pCEP4-HIF-1a and 0.1 mg pCDNA3-b-gal were added. Cells were incubated for 24 h under normoxic conditions or 4 h under normoxic conditions followed by 20 h under hypoxic conditions. Cells were lysed in 400 ml of cell culture lysis buffer (Promega Madison, WI, USA) and the lysate was analysed for luciferase and b-galactosidase activities. The luciferase assay and bgalactosidase activity assay were performed according to the protocols from the manufacturer (Promega Madison, WI, USA). Transfection efficiency was normalized on the basis of b-galactosidase activity.
Electrophoretic mobility shift assay
Oligonucleotide probes were generated by 5 0 end labeling with [g-32 P]ATP (Perkin-Elmer) and T4 polynucleotide kinase (BioLabs). Binding reactions were carried in a total volume of 20 ml containing 5 mg of protein extract and 0.1 mg of denatured herring sperm DNA (Sigma) in 10 mm Tris-HCl (pH 7.5), 50 mm KCl, 50 mm NaCl, 1 mm MgCl 2 , 1 mm EDTA, 5 mm DTT and 5% glycerol. Anti-HIF-1a (Santa Cruz Inc.) was mixed to extracts prior to probe where indicated. After preincubation for 5 min at room temperature, probes were added to the binding reactions and the incubation was continued for an additional 30 min. The reaction mixtures were then loaded onto a 5% nondenaturing polyacrylamide gel. Electrophoresis was performed at 180 V in a 0.3 Â TBE (1 Â TBE is 89 mm Tris-HCl, 89 mm boric acid and 5 mm EDTA) at 41C. Gels were vacuum dried and autoradiographed at À801C for 18-24 h.
Antisense experiments
Antisense oligonucleotide (5 0 -GCGCTCCGTTCTGCGA-CATG-3 0 ) (Sigma Genesys, Oakville, ON, Canada) and sense oligonucleotide (5 0 -GTACAGCGTCTTGCCTCGCG-3 0 ) were complimentary to bases À1 to þ 19 of the human Bnip3 gene. Random sequence oligonucleotide (5 0 -GCAGTCAGC-GACGTCGAAGC-3 0 ) contained the same bases in a scrambled sequence. Oligonucleotides were phosphorothioate modified to prevent degradation. Oligonucleotides were diluted in Opti-MEM (Gibco BRL) mixed with oligofectamine (Invitrogen) and incubated with HEK293 cells for 4 h then hypoxic medium was added and cells were further incubated under hypoxia for 24-48 h. At indicated times, cell death was determined via Trypan blue exclusion assay or cells were lysed and protein extracts were analysed for BNIP3 expression as described above.
Trypan blue cell death assay
Trypan blue exclusion assays were performed to identify compromised plasma membranes. Culture media were removed and replaced with 0.4% Trypan blue in PBS for 5 min at 371C. The percentage of dead cells was calculated by counting the number of blue cells in a population of clear cells. A total number of at least 200 cells were counted for each assay.
Electron microscopy
HEK293T cells with or without EGF stimulation (4 h) or pepstatin A (1 h) treatment were transfected with BNIP3. After 12 h of transfection, cells were collected and fixed in 2% paraformaldehyde, 0.1% glutaraldehyde in 0.1 m sodium cacodylate for 2 h, postfixed with 1% OsO 4 for 1.5 h, washed and finally stained for 1 h in 3% aqueous uranyl acetate. The samples were then washed again, dehydrated with graded alcohol, and embedded in Epon-Araldite resin (Canemco Inc.). Ultrathin sections were cut on a Reichert ultramicrotome, counterstained with 0.3% lead citrate and examined on a Philips EM420 electron microscope.
Results
In human HEK293 and MCF-7 cells, BNIP3 protein increases during hypoxia
Under hypoxic conditions, BNIP3 protein levels increase in rodent fibroblasts and mouse cardiomyocytes cells (Guo et al., 2001; Kubasiak et al., 2002; Regula et al., 2002) . BNIP3 protein was also shown increased in human solid tumors (Sowter et al., 2001) . To determine whether BNIP3 protein levels increase in human epithelial-derived cells under hypoxia, we exposed MCF-7 and HEK293 cells to hypoxic conditions over a 60 h time course in a hypoxic chamber and analysed BNIP3 expression in these cells by Western blotting. Hypoxic exposure resulted in an increased BNIP3 expression in MCF-7 cells at 12 h. BNIP3 expression remained increased for 48 h, and declined after 60 h (Figure 1) . In HEK293 cells, BNIP3 expression increased at 24 h and was maximally increased after 60 h These results indicate that BNIP3 expression increases during hypoxia in human epithelial-derived cells.
Hypoxia-induced cell death is blocked by either antisense oligonucleotide against BNIP3 or expression of human BNIP3 protein lacking the transmembrane domain BNIP3 is induced under hypoxic condition and upon forced overexpression of BNIP3, cells undergo cell death Vande Velde et al., 2000; Regula et al., 2002) . Furthermore, by blockage of BNIP3 expression in mouse cardiomyocytes, ischemia-induced cell death is inhibited (Kubasiak et al., 2002) . It is, however, unknown if BNIP3 is involved in hypoxiainduced cell death in human epithelial-derived cells. Using antisense oligonucleotides against BNIP3 to reduce expression, we determined if hypoxia-induced cell death was affected in HEK293 cells. For 48 h, HEK293 cells were treated with random, sense and antisense oligonucleotide against human BNIP3, and exposed to hypoxic conditions. To confirm that antisense oligonucleotides against BNIP3 are blocking its hypoxia induction, cells were lysed and Western blotted for BNIP3 expression. Only treatment with antisense oligonucleotides resulted in a significant decreased expression of BNIP3 protein as compared cells treated with random or sense oligonucleotides under hypoxic conditions (Figure 2a ). Oligonucleotide treatments had no significant effect on b-actin levels ( Figure 2a ). The amount of hypoxia-induced cell death was determined by trypan blue exclusion assay as described in Materials and methods section. At 48 h, hypoxic treatment resulted in 29, 28 and 27% cell death in nontransfected, random oligonucleotide-transfected and sense oligonucleotide-transfected cells, respectively ( Figure 2b ). In contrast, cells transfected with the antisense oligonucleotide against BNIP3 showed 12% cell death (Figure 2b ). This is comparable to the level of cell death under normoxia conditions (data not shown). Thus, the lower expression of BNIP3 protein in cells treated with antisense oligonucleotides correlated with a reduction in hypoxia-induced cell death. Deletion of the transmembrane domain of BNIP3 (BNIP3DTM) fails to induce cell death upon overexpression . In addition, BNIP3DTM acts as a dominant-negative protein blocking endogenous BNIP3 from integrating into the mitochondria . BNIP3DTM was transiently expressed in HEK293 cells and cells were exposed to hypoxic conditions for 48 h. Hypoxia-induced cell death was reduced from 30% for cells transfected with vector alone as a negative control to 18% for cells expressing BNIP3DTM (Figure 2c) . Transfection of vector alone into HEK293 cells resulted in similar levels of cell death compared to untransfected cells (data not shown). These results suggest that blockage of BNIP3 activity results in reduced hypoxia-induced cell death.
Hypoxic induction of human BNIP3 is mediated by transcription factor HIF-1a
One of the major mediators of hypoxia gene regulation is the transcription factor HIF-1a (Harris, 2002; Leek et al., 2002) . In rodent fibroblasts, BNIP3 upregulation is mediated by HIF-1a (Bruick, 2000) . Hypoxic regulation of the human BNIP3 protein is, however, unknown. MCF-7 cells were incubated under hypoxia or normoxia for a 72 h time course. Hypoxic exposure resulted in an increased expression of both BNIP3 and HIF-1a proteins in MCF-7 cells. Furthermore, increased HIF1a expression was detected at 24 h, while BNIP3 protein was only detected after 48 h. At 72 h, BNIP3 expression was still increased, whereas HIF-1a expression was significantly decreased (Figure 3a) . Neither BNIP3 nor HIF-1a was detectable in cells cultured under normoxic conditions (Figure 3a) . This indicates that HIF-1a might regulate BNIP3 expression.
To determine whether BNIP3 upregulation was HIF1a dependant, MCF-7 cells were transiently tranfected with HIF-1a and incubated under normoxic conditions. This resulted in increased expression of BNIP3 under normoxic conditions after 24 h (Figure 3b ). BNIP3 expression increased further under hypoxic conditions (Figure 3b ). This difference in the amount of BNIP3 expression could be due to only 30% of the cells being transfected with HIF-1a whereas all cells were exposed to hypoxia (data not shown). These results indicate that HIF-1a overexpression increases BNIP3 protein levels.
Previously, it was demonstrated that the rodent 0.5 kb BNIP3 promoter was activated by HIF-1a (Bruick, 2000) . We have isolated a human 1.2 kb BNIP3 promoter and placed it upstream of a luciferase reporter gene (Figure 4a ). The promoter activity was monitored in MCF-7, CHO parental and CHO HIF-1a-defective cells. Luciferase expression was induced 15-fold when MCF-7 cells were incubated for 19 h under hypoxic conditions or when cells were cotransfected with HIF-1a (Figure 4b) . Furthermore, expression with a dominantnegative form of HIF-1a blocked hypoxia-induced activation of the BNIP3 promoter. In addition, CHO parental and CHO HIF-1a-defective cells were transfected with the BNIP3 promoter construct. In CHO parental cells, hypoxia-induced a fourfold increase in luciferase activity of the BNIP3 promoter compared to normoxic conditions (Figure 4c ). In the CHO HIF-1a-defective cells, absence of functional HIF-1a lead to a complete loss of hypoxia-mediated responsiveness of the BNIP3 promoter (Figure 4c ). To confirm that loss of hypoxia responsiveness was due to the absence of a functional HIF-1a, HIF-1a was transfected in the CHO HIF-1a-defective cells. The restoration of functional HIF-1a resulted in a fourfold induction of luciferase activity from the BNIP3 promoter at 24 h post-transfection under both normoxic and hypoxic conditions. This induction was similar to the increase in luciferase activity in CHO parental cells exposed to hypoxic conditions (Figure 4c ). These results indicate that the human BNIP3 promoter is activated in response to hypoxia mediated by the transcription factor HIF-1a.
Human BNIP3 promoter has a HRE that binds to transcription factor HIF-1a and controls its hypoxic induction HIF-1a binds to a consensus 5 0 -RCGTG-3 0 site on target gene promoters to activate their transcriptional Results represent average relative luciferase activity of three independent experiments and error bars indicate standard deviation. (e) MCF-7 cells were incubated under either hypoxic or normoxic conditions for 24 h prior to protein extract preparation. Extracts were mixed with probes containing the human HRE2 site, the mutated HRE2 site, the HRE1 site and a probe containing a consensus HIF1a binding site (W18). Where indicated extracts were mixed with anti-HIF-1a antibodies prior to incubation with HRE 2 probes. Binding reactions were analysed by EMSA as described in Materials and methods section BNIP3 regulates hypoxia-induced cell death S Kothari et al activity (Giatromanolaki and Harris, 2001; Piret et al., 2002) . In the rodent BNIP3 promoter, a HRE site located at À234 bp was found to be essential for transcriptional activation (Bruick, 2000) . Analysis of the BNIP3 promoter showed two possible HRE sites (HRE1: 5 0 -CACGTC-3 0 located at À206 bp and HRE2: 5 0 CACGTG-3 0 located at À609 bp) that are almost identical to the consensus sequence. Comparison between the rodent and human BNIP3 promoter revealed that an 18 bp sequence was identical between the two species. This sequence contains a consensus HRE site found essential for hypoxic activation of the rodent promoter (Figure 4a ). HEK293 cells were transfected with the human wild-type BNIP3 promoter and exposed to normoxic conditions. This established a background luciferase activity of 1000 RLU. Under hypoxic conditions, the promoter activity increased. Cells transfected with the BNIP3 promoter mutated at HRE2 site and exposed for 19 h under hypoxia failed to increase luciferase activity (700 RLU, Figure 4d ). In contrast, luciferase activity of cells transfected with the BNIP3 promoter mutated at the HRE 1 site was increased under hypoxia to similar levels as the wild-type promoter for BNIP3 (Figure 4d ). This suggests that the HRE2 site in the BNIP3 promoter is required for hypoxia-induced activation of the promoter.
Since the BNIP3 promoter has a HRE site essential for its hypoxia-mediated activation, it remains unknown in both rodent and human whether HIF-1a directly binds to the HRE2 site in the promoter. Using oligonucleotides containing the HRE2 site or a mutated HRE2 site, HIF-1a binding to these probes was determined by electro mobility shift assay as described in Materials and methods section. A probe (W18) containing a consensus HRE was used as a positive control. Both W18 and HRE2 probes showed binding to HIF-1a under hypoxic conditions. Mutation in the HRE2 site resulted in the loss of HIF-1a binding under hypoxic conditions (Figure 4e ). The binding was specific for HIF-1a since using anti-HIF-1a antibodies resulted in a supershift (Figure 4e ). When the W18 and HRE2 probes were incubated with lysates from cells exposed to normoxic conditions, no binding could be detected. In addition, using a probe for HRE1 site, there was no detectable binding of HIF-1a under hypoxic conditions (Figure 4e ). This suggests that HRE2 site in the human BNIP3 promoter binds to HIF-1a.
Growth factors protect cells from BNIP3-mediated cell death
BNIP3 is a hypoxia-regulated protein that induces cell death upon overexpression in human epithelial-derived cells . In epithelial-derived tumors, BNIP3 is expressed in hypoxic regions where cells are resistant to cell death (Sowter et al., 2001) . This suggests a possible survival mechanism blocking BNIP3-induced cell death in these cells. Growth factors provide survival responses to cells and contribute to cancer progression (Chapman et al., 1999; Furstenberger and Senn, 2002; Gibson et al., 2002) . We determined whether growth factors provide a survival response against BNIP3-induced cell death. MCF-7 cells were treated with 1 mg/ml of EGF or IGF in 10% FBS media for 1 h and transiently cotranfected with BNIP3 and b-galactosidase plasmids in the presence of EGF or IGF. Overexpression of BNIP3 increased cell death from 13% of cells after 12 h to 35% after 36 h. In the presence of EGF or IGF, the percentage of BNIP3-induced cell death was reduced to 7% at 12 h and 23% at 36 h (Figure 5a ). This reflects a 40% protection against BNIP3-induced cell death at 12 and 18 h, and 30% protection at 24 and 36 h post-transfection. Treatment with EGF or IGF failed to change the expression levels of BNIP3 in transfected cells (data not shown). In addition, HEK293T cells were also determined for EGF protection against BNIP3-induced cell death and showed similar results (data not shown). Thus, growth factors protect cells from BNIP3-induced cell death.
BNIP3-transfected cells were characterized by rounded mitochondria with destroyed cisternae, extensive cytoplasmic vacuolization and electron-dense regions . EGF stimulation may affect these events. To determine this, HEK293T cells were tranfected with BNIP3. After 12 h post-transfection, cells were examined under transmission EM as described in Materials and methods section. BNIP3-transfected cells appear to have collapsed mitochondria, cytoplasmic vacuolization and appearance of electrondense regions (Figure 5b ). In contrast, BNIP3-transfected cells treated with EGF showed moderate swollen mitochondria with intact internal structure, no cytoplasmic vacuolization and no electron-dense regions (Figure 5b ). Taken together, these data suggest that EGF protection involves blocking BNIP3-mediated mitochondrial changes and cytoplasmic vacuolization. Indeed, EGF treatment reduces BNIP3-mediated loss of membrane potential and increase in ROS in the mitochondria (data not shown).
BH3 domain of BNIP3 mediates growth factor protection BNIP3 contains several defined domains such as the PEST domain (amino acids 54-81), a BH3 domain (amino acids 104-119) and a transmembrane domain (amino acids 164-184) (Yasuda et al., 1998; Cizeau et al., 2000; Ray et al., 2000; Farooq et al., 2001; Kim et al., 2002) . We determined whether the EGF protective effects are mediated through these domains. Deletions of the PEST domain, amino-terminus region or the BH3 domain in BNIP3 were transiently transfected in MCF-7 cells. Deletions of the amino-terminus region or the PEST domain of BNIP3 did not alter EGFor IGF-mediated protection (Figure 6a ). However, deletion of the BH3 domain abrogated the effect of EGF-or IGF-mediated protection. Similar results were also found in HEK293T cells (Figure 6b ). These results suggest that EGF or IGF requires an intact BH3 domain of BNIP3 to confer protection against BNIP3-induced cell death.
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Herceptin sensitizes cells to hypoxia-induced cell death
We have demonstrated that BNIP3 plays a role in hypoxia-induced cell death in human epithelial-derived cells. We have also determined that stimulation with EGF confers protection against BNIP3-induced cell death. This suggests that EGF signaling could prevent hypoxia-induced cell death. Inactivation of EGF receptors has been previously shown to increase cell death in epithelial-derived cells (Gibson et al., 1999 (Gibson et al., , 2002 . Using an inhibitory antibody against the EGF receptor ErbB2 (Herceptin) that is currently used in the treatment of breast cancer (Burris, 2000; Stebbing et al., 2000; Mrsic et al., 2001) , we determined if hypoxia-induced cell death is altered following treatment with Herceptin.
MCF-7 cells that express ErbB2 were incubated with increasing concentrations of Herceptin and exposed to hypoxia for 48 h. The amount of cell death increased from 10% for nontreated cells to 25% at 10 mg/ml Herceptin and 30% at 100 mg/ml Herceptin (Figure 7a ). Under normoxic conditions, the amount of cell death remained the same over the range of Herceptin concentrations used (Figure 7a ) Furthermore, treatment with 10 mg/ml Herceptin increased cell death from 10% at 0 h, 20% at 48 h and 40% at 96 h in MCF-7 cells incubated under hypoxic conditions (Figure 7b ). In the absence of Herceptin treatment, the percentage cell death of MCF-7 cells incubated under hypoxic conditions was only slowly increasing over the time course (Figure 7b ). Using another antibody used in cancer (b) HEK293T cells were transfected with empty vector or cDNA for BNIP3 in a pcDNA3 expression vector. Cells were also untreated or treated with EGF (1 mg/ml) in 10% FBS media for 18 h. The cells were visualized using electron microscope. Black arrows indicate where mitochondria and vacuoles are located under the appropriate heading. White arrows indicate electron-dense bodies. The images of the whole cell were magnified 7500 times whereas images of mitochondria and vacuoles were magnified 350 000 times BNIP3 regulates hypoxia-induced cell death S Kothari et al treatment (Rituxmab) failed to sensitize cells to hypoxiainduced cell death (data not shown). Herceptin treatment, however, failed to change hypoxia-induced BNIP3 expression levels (data not shown). These results indicate that inactivation of ErbB2 sensitizes cell to hypoxia-induced cell death.
Discussion
The relevance of hypoxia in epithelial-derived tumors is becoming increasingly important. Antiangiogenesis therapy has shown that hypoxic regions can survive and repopulate the tumor after therapy (Yu et al., 2002) . Hypoxic tumor cells are also more resistant to chemotherapy primarily due to the lack of an efficient way to deliver the drugs to these cells (Giatromanolaki and Harris, 2001; Koukourakis, 2001; Goonewardene et al., 2002) . Radiation that relies on the formation of ROS to induce apoptosis is also ineffective in hypoxic cells due to the low rate of oxidative phosphorylation (Koukourakis, 2001 ). In addition, hypoxic cells are under constant stress and are more likely to have genomic instability.
Mutations in genes such as p53 have been shown to arise from hypoxic regions in tumors (Yu et al., 2002) . Thus, targeting hypoxic-mediated cell death machinery such as BNIP3 is important in cancer treatment. BNIP3 is one of the most hypoxic-responsive genes with its mRNA and protein levels increasing to high levels following hypoxia (Caro, 2001; Guo et al., 2001) . Increased expression of BNIP3 induces cell death through mitochondrial dysfunction in many cell types including epithelial-derived cancer cells (Chen et al., 1999; Cizeau et al., 2000; Vande Velde et al., 2000) . In the present study, we have determined that blockage of BNIP3 induction or function reduces the amount of hypoxia-induced cell death in human epithelial cells. Furthermore, transcription factor HIF-1a is essential for BNIP3 transcriptional activation under hypoxia. It has been previously shown that rodent BNIP3 promoter is activated by HIF-1a (Bruick, 2000) . However, direct interaction between BNIP3 promoter and HIF-1a was not demonstrated. Herein, we have shown for the first time that HIF-1a could directly binds to a HRE site on the human BNIP3 promoter and this binding is required for activation of the human BNIP3 promoter. Furthermore, 1.2 kb human and 0.5 kb rodent BNIP3 promoter are not identical except for a 24 bp sequence wherein a consensus sequence for a BNIP3 regulates hypoxia-induced cell death S Kothari et al
